JP2004528293A - ピリミジン化合物並びに該化合物の製造及び使用方法 - Google Patents

ピリミジン化合物並びに該化合物の製造及び使用方法 Download PDF

Info

Publication number
JP2004528293A
JP2004528293A JP2002560642A JP2002560642A JP2004528293A JP 2004528293 A JP2004528293 A JP 2004528293A JP 2002560642 A JP2002560642 A JP 2002560642A JP 2002560642 A JP2002560642 A JP 2002560642A JP 2004528293 A JP2004528293 A JP 2004528293A
Authority
JP
Japan
Prior art keywords
group
compound
compounds
aryl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002560642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004528293A5 (cg-RX-API-DMAC7.html
Inventor
ガングジー,アレーム
Original Assignee
ドゥーケーン ユニバーシティ オブ ザ ホーリー ゴースト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドゥーケーン ユニバーシティ オブ ザ ホーリー ゴースト filed Critical ドゥーケーン ユニバーシティ オブ ザ ホーリー ゴースト
Publication of JP2004528293A publication Critical patent/JP2004528293A/ja
Publication of JP2004528293A5 publication Critical patent/JP2004528293A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2002560642A 2001-02-01 2002-01-23 ピリミジン化合物並びに該化合物の製造及び使用方法 Pending JP2004528293A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/775,064 US6423720B1 (en) 2001-02-01 2001-02-01 Pyrimidine compounds and methods for making and using the same
PCT/US2002/002358 WO2002060450A1 (en) 2001-02-01 2002-01-23 Pyrimidine compounds and methods for making and using the same

Publications (2)

Publication Number Publication Date
JP2004528293A true JP2004528293A (ja) 2004-09-16
JP2004528293A5 JP2004528293A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=25103214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002560642A Pending JP2004528293A (ja) 2001-02-01 2002-01-23 ピリミジン化合物並びに該化合物の製造及び使用方法

Country Status (6)

Country Link
US (2) US6423720B1 (cg-RX-API-DMAC7.html)
EP (1) EP1363637B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004528293A (cg-RX-API-DMAC7.html)
CA (1) CA2435958A1 (cg-RX-API-DMAC7.html)
DE (1) DE60213763D1 (cg-RX-API-DMAC7.html)
WO (1) WO2002060450A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502424A (ja) * 2009-08-17 2013-01-24 メモリアル スローン−ケタリング キャンサー センター 熱ショックタンパク質結合化合物、組成物、およびそれらを製造するための方法
US9878987B2 (en) 2014-05-13 2018-01-30 Memorial Sloan Kettering Cancer Center HSP70 modulators and methods for making and using the same

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423720B1 (en) * 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
PT1725540E (pt) 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
US8030319B2 (en) * 2005-02-10 2011-10-04 Duquesne University Of The Holy Ghost Methods for treating cancer and other pathological proliferating disorders by inhibiting mitosis using pyrrolo[2 3-d]pyrimidines
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
ES2562056T3 (es) 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
AU2006286576B2 (en) * 2005-09-01 2012-06-14 F. Hoffmann-La Roche Ag Diaminopyrimidines as P2X3 and P3X2/3 modulators
EP2440533B1 (en) 2009-06-12 2015-09-23 Socpra-Sciences Et Génie S.E.C. Guanine riboswitch binding compounds and their use as antibiotics

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08504765A (ja) 1992-12-16 1996-05-21 アグロン・ファーマシュウティカルズ・インコーポレーテッド 抗増殖性の置換5−チアピリミジノンおよび5−セレノピリミジノン化合物
EP0986252B1 (en) * 1993-06-04 2006-03-08 Sarnoff Corporation System and method for electronic image stabilization
US5426110A (en) * 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
EP0697788A3 (en) * 1994-08-19 1997-03-26 Eastman Kodak Co Adaptive and global motion compensated cancellation of the interlacing of successive video images with post-processing
US5973733A (en) * 1995-05-31 1999-10-26 Texas Instruments Incorporated Video stabilization system and method
EP0868815A2 (en) * 1996-10-24 1998-10-07 Koninklijke Philips Electronics N.V. Noise filtering
US6140351A (en) * 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
JP4389371B2 (ja) * 2000-09-28 2009-12-24 株式会社ニコン 画像修復装置および画像修復方法
US6423720B1 (en) * 2001-02-01 2002-07-23 Duquesne University Of The Holy Ghost Pyrimidine compounds and methods for making and using the same

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013502424A (ja) * 2009-08-17 2013-01-24 メモリアル スローン−ケタリング キャンサー センター 熱ショックタンパク質結合化合物、組成物、およびそれらを製造するための方法
US9567318B2 (en) 2009-08-17 2017-02-14 Memorial Sloan-Kettering Cancer Center Substituted pyrimidine compounds and uses thereof
US10052325B2 (en) 2009-08-17 2018-08-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US10758538B2 (en) 2009-08-17 2020-09-01 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US9878987B2 (en) 2014-05-13 2018-01-30 Memorial Sloan Kettering Cancer Center HSP70 modulators and methods for making and using the same
US10160729B2 (en) 2014-05-13 2018-12-25 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
US10647683B2 (en) 2014-05-13 2020-05-12 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same

Also Published As

Publication number Publication date
EP1363637A1 (en) 2003-11-26
EP1363637B1 (en) 2006-08-09
CA2435958A1 (en) 2002-08-08
WO2002060450A1 (en) 2002-08-08
US6423720B1 (en) 2002-07-23
EP1363637A4 (en) 2005-04-06
US20030040524A1 (en) 2003-02-27
DE60213763D1 (de) 2006-09-21

Similar Documents

Publication Publication Date Title
KR100226114B1 (ko) 항증식 작용을 가진 퀴나졸린 화합물
US8334307B2 (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
ES2968421T3 (es) Atropisomerismo para la selectividad potenciada de inhibidor de cinasa
JP5259398B2 (ja) 抗ガン剤耐性克服剤
EP3492468A1 (en) Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof
JP2023520595A (ja) ピラゾロピリダジノン化合物、その医薬組成物及びその用途
EP3865487A1 (en) Aromatic ring-linked dioxane-quinazoline or -quinoline compounds, compositions and use thereof
US20170015672A1 (en) Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
EP0482804B1 (en) Pyrrolo[2,3-d]pyrimidines with cardiovascular activity, process for their preparation and pharmaceutical compositions containing them
US6423720B1 (en) Pyrimidine compounds and methods for making and using the same
IE57675B1 (en) 5-pyrimidinecarboxamides and thiocarboxamides and treatment of leukemia and tumors therewith
CN104557913B (zh) 吡啶并嘧啶类化合物,其制备方法和用途
US11267810B2 (en) Aminopyrimidine compound and composition comprising same and use thereof
EP0290558B1 (en) Antifolate agents
US5990118A (en) Purine compounds and xanthine oxidase inhibitors
US12351583B2 (en) Triazolopyrimidines based on thymine nucleobase and methods for producing them
EP1556380B1 (fr) Derives de pyridoindolone substitues en -3 par un groupe heterocyclique, leur preparation et leur application en therapeutique
JPWO2018097295A1 (ja) ピリド[3,4−d]ピリミジン誘導体又はその溶媒和物の結晶
EP2885297B1 (fr) Pyrido[3,2-d]pyrimidines trisubstituées, leurs procédés de préparation et leurs utilisations en thérapeutique
JPH0441145B2 (cg-RX-API-DMAC7.html)
CA2140018A1 (en) Pyrimidine compounds used in the therapy
EP4608509A1 (en) New inhibitors of phosphatidylinositol 3-kinase
EP1390368B1 (en) Disubstituted 7,9-guaninium halides as telomerase inhibitors
HK40057704A (en) Aromatic ring-linked dioxane-quinazoline or -quinoline compounds, compositions and use thereof
JP2000038389A (ja) ピラゾロピリミジン化合物及びキサンチンオキシダーゼ阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090127